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REGULAR ARTICLE

Safety and activity of varlilumab, a novel and ﬁrst-in-class agonist
anti-CD27 antibody, for hematologic malignancies
Stephen M. Ansell,1 Ian Flinn,2 Matthew H. Taylor,3 Branimir I. Sikic,4 Joshua Brody,5 John Nemunaitis,6 Andrew Feldman,1
Thomas R. Hawthorne,7 Tracey Rawls,7 Tibor Keler,7 and Michael J. Yellin7
1
Division of Hematology, Mayo Clinic, Rochester, MN; 2Center for Blood Cancer, Sarah Cannon Research Institute, Nashville, TN; 3Franz Cancer Center, Providence Portland
Medical Center, Portland, OR; 4Clinical and Translational Research Unit, Stanford Cancer Institute, Stanford, CA; 5Division of Hematology and Oncology, Mount Sinai Medical
Center, New York, NY; 6Division of Hematology, University of Toledo College of Medicine and Life Sciences, Toledo, OH; and 7Celldex Therapeutics, Inc., Hampton, NJ

Key Points

• The anti-CD27 agonist
antibody varlilumab was
well tolerated in lymphoma patients with no
maximum tolerated
dose identified.
• Varlilumab transiently increased pro-inflammatory
cytokines and led to a
durable complete response in a patient with
refractory Hodgkin
lymphoma.

CD27, a costimulatory molecule on T cells, induces intracellular signals mediating cellular
activation, proliferation, effector function, and cell survival on binding to its ligand, CD70.
Varlilumab, a novel, ﬁrst-in-class, agonist immunoglobulin G1 anti-CD27 antibody, mediates
antitumor immunity and direct killing of CD271 tumor cells in animal models. This ﬁrst-inhuman, dose-escalation, and expansion study evaluated varlilumab in patients with
hematologic malignancies. Primary objectives were to assess safety and the maximum
tolerated and optimal biologic doses of varlilumab. Secondary objectives were to evaluate
pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. In a
3 1 3 dose-escalation design, 30 patients with B-cell (n 5 25) or T-cell (n 5 5) malignancies
received varlilumab (0.1, 0.3, 1, 3, or 10 mg/kg IV) as a single dose with a 28-day observation
period, followed by weekly dosing (4 doses per cycle, up to 5 cycles, depending on tumor
response). In an expansion cohort, 4 additional patients with Hodgkin lymphoma received
varlilumab at 0.3 mg/kg every 3 weeks (4 doses per cycle, up to 5 cycles). No dose-limiting
toxicities were observed. Treatment-related adverse events, generally grade 1 to 2, included
fatigue, decreased appetite, anemia, diarrhea, and headache. Exposure was linear and doseproportional across dose groups and resulted in increases in proinﬂammatory cytokines
and soluble CD27. One patient with stage IV Hodgkin lymphoma experienced a complete
response and remained in remission at .33 months with no further anticancer therapy.
These data support further investigation of varlilumab for hematologic malignancies,
particularly in combination approaches targeting nonredundant immune regulating
pathways. This trial was registered at www.clinicaltrials.gov as #NCT01460134.

Introduction
CD27, a member of the tumor necrosis factor receptor superfamily, acts as a potent costimulatory
molecule that, unlike other related family members, is expressed constitutively on unstimulated
T lymphocytes. CD27 is also expressed on B lymphocytes and is commonly expressed on nearly all
subtypes of mature B-cell lymphomas.1,2 CD70, the ligand for CD27, is transiently expressed on
Submitted 8 October 2019; accepted 2 March 2020; published online 7 May 2020.
DOI 10.1182/bloodadvances.2019001079.
This article is a continuation of a previous report.15
Presented in abstract form at the 2014 Society for Immunotherapy of Cancer Annual
Meeting, National Harbor, MD, 7-9 November 2014 (Abstract 52514/Poster P115);
the 2014 American Society of Clinical Oncology Annual Meeting, Chicago, IL, 30 May3 June 2014 (Abstract ID #1127/Poster); and the 2013 Society for Immunotherapy of
Cancer Annual Meeting, National Harbor, MD, 8-10 November 2013 (Abstract
1771910/Poster 146).
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Deidentified individual participant data that underlie the reported results will be made
available 6 months after publication for a period of up to 3 years following the
publication date. Proposals for access should be sent to info@celldex.com. The study
protocol is included as a data supplement available with the full-text version of this
article.
The full-text version of this article contains a data supplement.
© 2020 by The American Society of Hematology
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IMMUNE ACTIVATION

EFFECTOR FUNCTION

Figure 1. Mechanism of varlilumab antitumor activity.
Interaction of CD27 and CD70 (A) and varlilumab and the Agspecific TCR (B) in the immune activation of effector T cells.
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antigen-presenting cells. CD27/CD70–mediated costimulation,
concomitant with antigen-specific T-cell receptor (TCR) stimulation,
results in T-cell activation, proliferation, survival, maturation of effector
capacity, and T-cell memory (Figure 1).3,4 CD27-CD70 interactions
also promote B-cell proliferation, generation of plasma cells,
production of immunoglobulin, and B-cell memory,5-8 as well as
the induction of natural killer cell cytolytic activity.9 CD27 is also
expressed by T regulatory cells (Tregs) and may have a role in their
expansion and activation.10
Varlilumab (CDX-1127) is a novel, first-in-class fully human immunoglobulin G1 kappa anti-CD27 monoclonal antibody that acts as
an agonist of CD27 by interaction with the CD70-binding site.11
Varlilumab mimics CD70 to enhance the CD27-mediated T-cell
costimulatory pathway when combined with TCR activation
(Figure 1). Potent cytokine release and proliferation of T cells
were observed when purified human T cells were cultured with
varlilumab and OKT3 (TCR-stimulating antibody).12 Varlilumab
has an unmodified Fc region allowing for Fc receptor–mediated
crosslinking and Fc-dependent effector function such as antibodydependent cellular cytotoxicity.
Varlilumab has potent antitumor activity in multiple animal models.13,14
For example, BCL1 B-lymphoma and CT26 (colon cancer) tumor
challenge models using human CD27-transgenic mice showed that
treatment with varlilumab resulted in substantially improved survival
at high repeated dose levels (.150 mg 3 5); a biologically effective
response was observed for $0.5 mg/kg 3 5 repeated doses. In
addition, varlilumab exhibited potent antitumor activity against the
EG7 mouse thymoma in syngeneic tumor models that rely on
T cell–mediated immunity for response. In xenograft models in SCID
mice, varlilumab showed significant antitumor effects against
a variety of human tumor cell lines, including the lymphoblastic
Burkitt’s lymphoma–derived cell lines (Raji, Daudi, and Namalwa)
and an acute lymphocytic leukemia cell line (CCRF-CEM). In
addition to the enhanced immune activation of cells, preclinical
studies with varlilumab have shown direct therapeutic effects
against CD27-expressing tumors. Together, these data provide
1918
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support for targeting CD27 in hematologic malignancies as a mechanism to enhance antitumor immunity, as well as to mediate direct
killing of CD27-expressing lymphomas.
The current first-in-human, phase 1, open-label, dose-escalating,
and expansion study was conducted to assess the safety,
pharmacokinetics, pharmacodynamics, and activity of varlilumab
when administered as monotherapy to patients with advanced
malignancies. Patients with solid tumors and hematologic malignancies were separately enrolled in parallel dose-escalation and
expansion phases, given the potential for differing mechanisms of
action, pharmacokinetics, and toxicity profile of anti-CD27–directed
therapy in these populations. In the dose-escalation and expansion
cohorts of patients with solid tumors (n 5 56), varlilumab was well
tolerated and showed clear evidence of biological and clinical
activity.15 Durable clinical activity was observed in 2 patients with
renal cell carcinoma. One patient achieved a partial response on
study (78% shrinkage of target lesions and progression-free survival
of .3.6 years). A second patient had stable disease for .3.9 years
without additional therapy. This report provides results for the patients
with hematologic malignancies enrolled in the phase 1 study.

Methods
Patients
The dose-escalation study portion included patients with a histologic diagnosis of any B-cell or T-cell malignancy, whereas the
expansion cohort was restricted to patients with Hodgkin lymphoma. All patients were required to have disease that was
progressive subsequent to previous therapies with no remaining
alternative approved therapy options. Additional eligibility requirements included measurable or evaluable disease as per appropriate
disease-specific staging criteria; $18 years of age; life expectancy
$12 weeks; Eastern Cooperative Oncology Group performance
status of 0 or 1; adequate renal, hepatic, and bone marrow function;
and resolution of toxicity related to prior therapy (excluding alopecia)
to grade 1 or lower. A washout of $4 weeks was required
12 MAY 2020 x VOLUME 4, NUMBER 9
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Figure 2. Study design/treatment schema. (A) Using a standard 3 1 3 design, the B-cell malignancy and T-cell malignancy dose escalations proceeded separately.
Patients who did not complete the multidose phase for reasons other than DLT were replaced as necessary. The B-cell malignancy dose escalation completed through the
maximum planned dose level (10 mg/kg). After the B-cell malignancy dose escalation component of the study, an expansion cohort was enrolled to further explore the clinical
and biological activity of varlilumab (at 0.3 mg/kg every 3 weeks) in patients with Hodgkin lymphoma. The study was closed after treatment of 4 patients in the Hodgkin
lymphoma expansion cohort and 5 patients at the 3 mg/kg dose level in the T-cell malignancy dose-escalation phase. (B) During the dose-escalation phase, varlilumab (represented by red circles) was initially administered as a single dose with 28-day observation. Additional multidose treatment (4 weekly doses with a 4-week observation) and
retreatment (up to 4 additional cycles, each consisting of 4 weekly doses with an 8-week observation) were allowed for patients who had not experienced progressive disease
or DLT. Patients in the Hodgkin lymphoma expansion cohort received varlilumab at 0.3 mg/kg, every 3 weeks (up to 5 cycles, each consisting of 4 doses). Diagnostic imaging
and restaging were repeated every 12 weeks (as indicated by asterisks).

for chemotherapy, monoclonal-based therapies, systemic radiation
therapy, and immunosuppressive medications, including systemic
corticosteroids. Other immunotherapy, investigational drugs, and
previous focal radiotherapy were prohibited within 2 weeks of study
entry. Patients were excluded who were: pregnant; breastfeeding;
or who had other prior malignancies within the last 5 years, active
brain metastases, autoimmune disease, active infection, significant
cardiovascular disease, or any other significant, active, concurrent
medical illness that would have precluded study treatment.
The study was conducted at each of the participating institutions in
accordance with the Declaration of Helsinki and Good Clinical
Practice Guidelines, after approval by a local institutional review
board and in accordance with an assurance filed with and
approved by the Department of Health and Human Services, where
appropriate. All patients signed written informed consent before
initiation of any protocol-specific procedures. All authors had
access to primary clinical trial data. This trial was registered at www.
clinicaltrials.gov as #NCT01460134.

Study design and treatment
Study design and treatment schema are shown in Figure 2. Dose
escalation followed a standard 3 1 3 design16 to evaluate the safety
12 MAY 2020 x VOLUME 4, NUMBER 9

and tolerability of varlilumab, and, if possible, to determine the
maximum tolerated dose and/or optimal biologic dose in patients
with hematologic malignancies. The maximum tolerated dose was
defined as the highest dose in which #1 of 6 patients experienced
a dose-limiting toxicity (DLT). DLT was defined as any grade 3 or
higher treatment-related toxicity, excluding grade 3 inflammation
due to local therapeutic response persisting #7 days; grade 3
nonmalignant lymphocyte changes that improved to grade 2 or
lower or within 20% of baseline within 28 days; and grade 3
nausea, vomiting, or diarrhea that resolved to grade 1 or lower
within 48 hours.
Varlilumab dose levels of 0.1, 0.3, 1, 3, and 10 mg/kg were selected
for the initial dose escalation in patients with B-cell malignancies,
based on the no observable effect level of 25 mg/kg identified
during nonclinical toxicology and to bridge the dose ranges with
expected clinical activity. Subsequently, an abbreviated dose
escalation (3 and 10 mg/kg) was initiated for patients with T-cell
malignancies. In the dose-escalation study portion, varlilumab was
initially administered as a single dose followed by a 4-week
evaluation period. Additional multidose treatment (4 weekly doses
with a 4-week observation) and retreatment (up to 4 additional cycles,
each consisting of 4 weekly doses with an 8-week observation
VARLILUMAB FOR HEMATOLOGIC MALIGNANCIES
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period) were allowed for patients who had not experienced
progressive disease or DLT.

specific anti-human IgG horseradish peroxidase conjugate for
detection. The assay is validated with a sensitivity of 180 ng/mL.

After completion of the dose-escalation phase, an expansion cohort
was initiated to further evaluate the clinical and biological activity of
varlilumab in up to 15 patients with Hodgkin lymphoma at the
0.3 mg/kg dose given every 3 weeks.

Immunogenicity samples were collected prestudy, before the first
dose, and at 1 week after the last dose in each multidose cycle, and
at the time of study discontinuation. Anti-drug antibodies (ADAs)
were determined by a bridging ELISA and a cut-point based on a 5%
false-positive rate. Positive samples were confirmed in a secondary
assay to determine specificity of response by immunodepletion with
study drug and a cut-point based on a 1% false-positive rate, as
previously described.15

All patients received varlilumab as a 90-minute IV infusion, with
a 4- to 6-hour observation after the first 2 infusions and a 2-hour
observation after each subsequent dose. For the first dose in
the dose-escalation portion, patients received 10% of the total
dose over 10 minutes followed by a 1-hour observation before
administration of the remaining dose over 80 minutes.

Assessments
Safety assessments included vital signs, physical examinations,
laboratory test results, electrocardiograms, and Eastern Cooperative Oncology Group performance status. Patients were monitored
for toxicity through 70 days posttreatment. Given the expected
mechanism of action of varlilumab, particular attention was given to
adverse events such as diarrhea/colitis, rash, endocrinopathies,
and hepatitis, which have been observed with other immune
antibodies and may be related to immune activation.17 Patients
were also closely monitored for infusion reactions or cytokine
release syndrome.18 Adverse events were coded with the latest
available version of the Medical Dictionary for Regulatory Activities
and graded according to the National Cancer Institute–issued
Common Terminology Criteria for Adverse Events version 4.0.
Diagnostic imaging for assessment of tumor response was performed
every 12 weeks. Antitumor activity was assessed by the investigator
using the International Working Group response criteria for nonHodgkin lymphoma, the Cheson criteria for Hodgkin lymphoma, or
other appropriate disease-specific criteria.
Pretreatment tumor samples cut serially at 5 mm were collected for
CD27 staining. The tissue sections were deparaffinized in 3
changes of xylene and cleared through graded ethanol series.
Endogenous peroxidase was quenched by incubation in 50%
methanol/H2O2. After rinsing with tap water, all sections were
pretreated for 30 minutes with 50 mM EDTA, pH 8.0 using
a steamer and cooled for an additional 5 minutes. All immunohistochemical staining was performed automatically on a DAKO
Autostainer Plus using the following antibodies and their corresponding detection systems: CD27 (1 mg/mL; Abcam, ab#131254,
1:1000) or mouse immunoglobulin G1 control (DAKO, #x0931,
1:100000). All sections were stained with hematoxylin and rinsed well
in tap water. All slides were observed with light microscopy (Olympus
AX70, 2003/aperture 0.46, 4003/aperture 0.75, 6003/aperture
0.80; Olympus America) with images captured with a SPOT RT
camera and software (Diagnostic Instruments).
Serial serum samples were collected for pharmacokinetic analyses
from 30 patients receiving from 0.1 to 10 mg/kg varlilumab through
28 days after the first varlilumab dose and the fourth weekly
varlilumab dose. Trough (predose) and peak (30 minutes after
completion of the infusion) samples were collected for all other
infusions. Serum levels of varlilumab were determined by
enzyme-linked immunosorbent assay (ELISA), using murine Fchuman CD27 fusion protein for capture and a goat F(ab9)2
1920
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Cytokines associated with T-cell function, immune regulation,
and cell migration pretherapy and posttherapy were measured.
Serum samples were analyzed by using a multiplex enzyme-linked
immunosorbent assay (Thermo Fisher Scientific) to measure 30
serum cytokines. A Luminex 200 System, version 1.7, was used for
reading plates, and MasterPlex QT 1.0 system (MiraiBio) was used
to analyze data. Cytokines included the following: epidermal
growth factor, eotaxin, basic fibroblast growth factor, granulocyte
macrophage–colony stimulating factor, hepatocyte growth factor,
interferon-a, interferon-g, interleukin 1 receptor antagonist (IL-1RA),
IL-1b, IL-2, IL-2R, IL-4 to IL-8, IL-10, IL-12, IL-13, IL-15, IL-17,
inducible protein-10 (CXCL10), monocyte chemotactic protein 1,
monokine induced by interferon-g (CXCL9), macrophage inflammatory protein-1a (MIP-1a/CCL3), MIP-1b (CCL4), regulated on activation normal T-cell expressed and secreted protein,
tumor necrosis factor-a, and vascular endothelial growth factor
(VEGF). Internal control serum was included in all assays to
control for interassay variation, and controls were randomized
across plates.
Mean levels of soluble CD27 were assessed by using a sandwich
ELISA that is not obstructed by the presence of bound varlilumab,
as previously described.15 Whole blood was collected and
processed into peripheral blood mononuclear cells with Ficoll and
frozen for analysis by flow cytometry. Peripheral blood mononuclear
cells were thawed and stained with the following antibodies: CD3
FITC, CD8 PerCP, CD4 PE, and FoxP3 Alexa 488. Cells were first
gated on lymphocytes and then subsequently gated on the
fluorescence of the cell of interest. Percentages of positive cells
were calculated as a percentage of the lymphocytes.

Statistical considerations
The primary study objectives were to assess safety and the maximum
tolerated and optimal biologic doses of varlilumab. Secondary study
objectives were to evaluate pharmacokinetics, pharmacodynamics,
immunogenicity, and antitumor activity.
Pharmacokinetic parameters were derived via noncompartmental
analysis of individual patient serum drug levels using NCA Plasma
Model 200-202 (Phoenix WinNonlin 8.0; Certara L.P. [Pharsight]).
Briefly, elimination half-life and exposure parameters were estimated
following visual inspection of dose 1 and 5 time vs concentration
profiles to identify the terminal phase, and goodness-of-fit criteria
were used to refine the terminal phase for each patient. Area under
the curve was calculated by using the linear trapezoidal rule with
linear interpolation with uniform weighting. All calculations were
based on actual sampling times and infusion durations, including
test infusion in dose 1.
12 MAY 2020 x VOLUME 4, NUMBER 9

Table 1. Pretreatment patient demographic and disease characteristics
B-cell malignancies dose
escalation (n 5 25)

Characteristic

T-cell malignancies dose
escalation (n 5 5)

Hodgkin lymphoma expansion
cohort (n 5 4)

Age, y
Median (range)

57 (23-92)

68 (57-77)

45 (22-79)

$65

8 (32)

3 (60)

1 (25)

Male sex

16 (64)

3 (60)

1 (25)

0

9 (36)

0 (0)

0 (0)

1

16 (64)

5 (100)

4 (100)

I

0 (0)

1 (20)

0 (0)

II

0 (0)

2 (40)

0 (0)

III

7 (28)

1 (20)

1 (25)

IV

18 (72)

1 (20)

3 (75)

ECOG performance status

Stage at study entry

B-cell tumor type
Diffuse large B cell
Follicular

10 (40)

0 (0)

0 (0)

6 (24)

0 (0)

0 (0)

Other non-Hodgkin B cell

2 (8)

0 (0)

0 (0)

Hodgkin

7 (28)

0 (0)

4 (100)

T-cell tumor type
Peripheral T-cell lymphoma

0 (0)

2 (40)

0 (0)

Cutaneous T-cell lymphoma

0 (0)

1 (20)

0 (0)

Mycosis fungoides

0 (0)

2 (40)

0 (0)

Time since diagnosis, median (range), y

7.2 (1.4-17.3)

6.6 (0.7-27.4)

7.0 (1.8-11.1)

Prior treatments received
Check-point blockade (CTLA-4 or PD-1)

0 (0)

1 (20)

3 (75)

Cytotoxic chemotherapy

25 (100)

5 (100)

4 (100)

Autologous transplant

11 (44)

0 (0)

3 (75)

Data are presented as n (%) unless otherwise specified.
CTLA-4, cytotoxic T lymphocyte antigen-4; ECOG, Eastern Cooperative Oncology Group; PD-1, programmed cell death 1.

For the pharmacodynamic end points, significant differences were
calculated by using a 2-tailed Student t test using paired or
unpaired data.

Results

with a median of 5 (range, 1-12) previous anticancer therapies.
All patients had received at least 1 previous line of cytotoxic
chemotherapy, 12% had received checkpoint inhibition, and 48%
had undergone autologous transplant.

Study treatments and tolerability

Patient characteristics
Thirty-four patients were enrolled at 7 centers from April 2012 to
June 2015 (Figure 2). Twenty-five patients with B-cell malignancies
were treated with varlilumab in the initial dose escalation, which was
completed through the maximum planned dose level (10 mg/kg).
Subsequent to recruitment challenges in the T-cell dose-escalation
and Hodgkin lymphoma expansion cohorts, which enrolled 5
patients and 4 patients, respectively, the study was closed.
Pretreatment demographic and disease characteristics for enrolled
patients are shown in Table 1. Of the treated patients, 18 had B-cell
non-Hodgkin lymphoma (10 diffuse large B-cell, 6 follicular, and 2
not specified), 11 had Hodgkin lymphoma, 3 had T-cell lymphoma,
and 2 patients had mycosis fungoides. The majority (91%) had
stage III or IV disease. Enrolled patients were heavily pretreated,
12 MAY 2020 x VOLUME 4, NUMBER 9

Patients received a median of 4 (range, 1-21) varlilumab doses on
study. Eighteen patients completed at least 1 multidose cycle of
varlilumab. Four of these patients received multiple treatment
cycles, ranging from 2 to 4.
Varlilumab, at doses up to 10 mg/kg in B-cell malignancies and
3 mg/kg in T-cell malignancies, was well tolerated without DLT. The
most frequently reported treatment-related adverse events (supplemental Table 1) were fatigue (8 [24%]), decreased appetite
(6 [18%]), anemia (4 [12%]), headache (3 [9%]), and diarrhea
(3 [9%]). Except for one grade 3 event of transient increased blood
alkaline phosphatase levels, treatment-related events were all grade
1 to 2 in severity. One patient discontinued study treatment after the
first varlilumab dose (10 mg/kg) due to grade 1 vision changes,
assessed as related to treatment by the investigator. The most
VARLILUMAB FOR HEMATOLOGIC MALIGNANCIES
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Jan 2013
(Baseline)

April 2013
(2.8 months, SD)

July 2013
(5.8 months, PR)

Oct 2013
(8.6 months, CR)

Figure 3. Patients with stage IV Hodgkin lymphoma with complete response (CR) to varlilumab. PR, partial response; SD, stable disease.

common reason patients discontinued treatment was because
of progressive disease (22 [65%]) or symptomatic deterioration
(7 [21%]). Two patients (6%) requested to discontinue treatment; 1
patient each (3%) discontinued due to death, lost to follow-up, and
a grade 1 adverse event of vision change (described earlier). There
were no unexpected or high-grade toxicities in patients who
previously received immune checkpoint blockade therapy.

Antitumor activity
Hodgkin lymphoma. Eleven patients with Hodgkin lymphoma
were enrolled. Of the 10 evaluable patients, there was 1 complete
response, 1 patient with stable disease, and the remaining patients
had progressive disease. The patient with a complete response was
a 28-year-old woman with stage IV Hodgkin lymphoma who had
previously experienced an inadequate response to induction
therapy and progression after 4 subsequent regimens, including
hematopoietic stem cell transplantation followed by brentuximab
vedotin consolidation. The patient had not previously received
treatment with anti–programmed cell death 1 (PD-1) or anti–
programmed death-ligand 1 therapy. After 3 cycles of varlilumab
therapy (0.3 mg/kg), the patient had a complete response (Figure 3).
Although varlilumab was discontinued with achievement of the
complete response, the patient remained in remission without further
anticancer therapy at the last follow-up, .33 months after enrollment
in the study.
Non-Hodgkin lymphoma. Of 18 patients with B-cell nonHodgkin lymphoma, there was no objective response, and 3 patients
experienced stable disease. A 67-year-old man with stage III
follicular lymphoma who had previously received multiple courses of
therapy, including combination chemotherapy, rituximab, ibritumomab
1922
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tiuxetan, and traditional radiation therapy, experienced stable
disease for 5.6 months with varlilumab (0.3 mg/kg). The tumor
response included 36% shrinkage of measurable disease, with
complete disappearance of disease in inguinal and iliac regions. A
52-year-old man with recurrent stage IV follicular lymphoma who
received a single dose of varlilumab 0.3 mg/kg followed by 5
treatment cycles at 0.1 mg/kg experienced stable disease for
14 months. Finally, a 58-year-old man with stage IV follicular
lymphoma, who had received 6 previous courses of therapy,
including combination chemotherapy, rituximab, ibritumomab
tiuxetan, and experimental therapy, experienced stable disease
for 4.5 months while receiving varlilumab (0.1 mg/kg). One patient
with T-cell non-Hodgkin lymphoma experienced stable disease,
and the other 4 patients with T cell non-Hodgkin lymphoma
experienced progressive disease.
CD27 expression. Pretreatment tumor samples were sufficient
for analysis of CD27 expression for 18 patients (supplemental
Table 2). The 2 follicular lymphomas analyzed had the highest
intensity of tumor expression, although apparently less lymphocyte
infiltration. The remaining lymphomas (nine Hodgkin lymphoma, five
diffuse B cell, and two T cell) had lower levels of tumor expression,
including 5 Hodgkin lymphoma and 4 diffuse B-cell with no tumor
staining. However, all of these showed CD27 staining of infiltrating
lymphocytes.
Notably, the pretreatment tumor sample for the patient with Hodgkin
lymphoma who experienced a complete response exhibited the
highest level of CD27 expression on infiltrating lymphocytes, relative
to the other patients with Hodgkin lymphoma. Reed-Sternberg cells
were CD27 positive (Figure 4).
12 MAY 2020 x VOLUME 4, NUMBER 9

Figure 4. Immunohistochemistry of a pretreatment
lymph node biopsy sample from a patient with

A

B

C

D

complete response to varlilumab. (A) Hematoxylin and
eosin stain (magnification 320) from a patient with
classical Hodgkin lymphoma. (B) Atypical lymphohistiocytic infiltrate within a background of normal reactive cells
(magnification 3100). (C) CD27 expression on malignant
cells, intratumoral lymphocytes, and histiocytes. Malignant
cells and intratumoral T cells were positive for CD27
expression (magnification 3100). (D) CD70 staining was
negative on both malignant cells and the intratumoral
immune infiltrate (magnification 3100).

Pharmacokinetics, immunogenicity,
and pharmacodynamics

most prominent effect at the 10 mg/kg dose (supplemental
Figure 1). The level of chemokines, particularly MIP-1b (CCL4)
and monocyte chemoattractant protein-1 (CCL2), showed a marked
transient elevation after the initial dose of varlilumab, consistent with
an inflammatory response (Figure 6A-B). Other soluble markers of
inflammation, such as monokine induced by interferon-g (CXCL9)
and IL-12, were significantly increased compared with baseline
values during the weekly dosing phase (Figure 6C-D). The changes
in chemokines and cytokines were not dose dependent, as similar
effects were observed in each cohort (not shown).

Varlilumab exposure was dose proportional, with a mean elimination
half-life ranging from 2.9 days (0.3 mg/kg) to 12.5 days (3 mg/kg)
after day 1 dosing (Figure 5; supplemental Table 3). Following
steady-state dosing, the elimination half-life ranged from 4.3 days
(0.3 mg/kg) to 14.5 days (10 mg/kg), which is consistent with the
pharmacokinetic results from dose escalation of human monoclonal
antibodies in patients with solid malignancies.15 There were no
specific on-study anti-varlilumab antibodies detected.

Varlilumab administration was associated with a decrease in the
absolute lymphocyte count in some patients that was generally
low grade, stable during continued treatment, and not associated

We observed significant changes in several soluble factors present
in serum. The levels of soluble CD27 were markedly increased after
varlilumab treatment and were generally dose dependent, with the
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with a clear dose effect. However, analysis of peripheral blood
lymphocyte populations by using flow cytometry did not reveal
consistent and significant changes in percentage of CD81 T cells
or CD41 T cells across the various dose levels (supplemental
Figure 2). A transient or maintained decrease in CD41 Tregs was
observed in some patients (supplemental Figure 3) but less
consistently than reported for patients with solid tumors treated
with varlilumab.15

Discussion
This first-in-human study in patients with hematologic malignancies evaluated the safety, pharmacokinetics, pharmacodynamics,
and early activity of varlilumab, an agonist anti-CD27 monoclonal antibody. Varlilumab doses up to 10 mg/kg weekly were well
tolerated with no DLT, and a maximum tolerated dose was not
identified.
Evidence of single-agent clinical activity was seen in this heavily
pretreated population of patients with advanced disease. One
patient with heavily pretreated, stage IV Hodgkin lymphoma,
including para-aortic involvement and B-symptoms, experienced
a complete response to varlilumab (0.3 mg/kg) that persisted as
of the last follow-up at nearly 3 years; 3 patients experienced
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stable disease ranging from 4.5 to 14 months. The kinetics of the
complete response were consistent with an immune-mediated
mechanism, with an initial increase in tumor that gradually
disappeared after 2 subsequent cycles. Interestingly, this patient
also had an abundance of CD271 tumor-infiltrating lymphocytes
and the Reed-Sternberg cells were CD27-positive; in contrast
the Reed Sternberg cells were CD27-negative in the majority of
Hodgkin lymphomas analyzed. This suggests the potential that
varlilumab may have benefited this patient via dual mechanisms
(ie, that the clinical response was mediated by an antitumor
immune response and potentially by direct killing of the tumor
cells).
It is interesting to note that among hematologic malignancies,
the PD-1 inhibitors have shown the greatest activity in Hodgkin
lymphoma. During the course of this study, data became available
showing that nivolumab resulted in an 87% objective response rate,
with 17% achieving a complete response in refractory classical
Hodgkin lymphoma.19 However, activity of checkpoint blockade in
non-Hodgkin lymphoma has been relatively modest, with primary
mediastinal large B-cell lymphoma showing an overall response rate
of 40% to 45% and other non-Hodgkin lymphoma subtypes being
less responsive, with an overall response rate of 3% to 10%.
12 MAY 2020 x VOLUME 4, NUMBER 9

In this study, varlilumab exhibited clinical benefit in 1 patient with
Hodgkin lymphoma (14%) who had a durable complete response
among the 7 PD-1 blockade-naive patients with Hodgkin lymphoma.
No responses were observed among the 3 patients with Hodgkin
lymphoma who had previously received PD-1 blockade. Four
patients with Hodgkin lymphoma were treated with a lower and
less frequent varlilumab dosing regimen of 0.3 mg/kg on a 3-week
schedule to potentially avoid overstimulation of T cells, but no
clinical responses were observed. The only distinguishing factor
identified in the 1 responding Hodgkin lymphoma patient relative to
the nonresponders was the marked intensity of the CD27expressing, tumor-infiltrating T cells in the responder, and possibly
also the presence of CD27 expressing Reed Sternberg cells.
However, CD27 expression did not correlate with clinical benefit in
any of the other patients.
Varlilumab exposure was dose proportional from 0.1 to 10 mg/kg,
with half-lives ranging from 3 to 12.5 days, which is consistent with
the pharmacokinetic results from dose escalation in patients with
solid malignancies.15 Accumulation was not calculated because
the dosing intervals were not equivalent from the first to the fifth
dose, but visual analysis of trough levels in dose escalation and
retreatment patients indicate accumulation for all doses at a weekly
interval (Figure 5). Screening ADA testing resulted in a 13%
positivity rate, exceeding the 5% false-positive target, but specific
ADAs were not detected posttreatment, even in patients with
multiple cycles (up to 13 doses) of varlilumab. Because the
varlilumab ADA assay is susceptible to interference from circulating
levels of drug .100 ng/mL, ADAs in some patients may be masked.
However, visual inspection of pharmacokinetic profiles did not
reveal any evidence of attenuated exposure following repeat dosing,
suggesting that ADA response is minimal.
We observed a significant dose-dependent increase in soluble
CD27, which we believe reflects the stabilization of shed CD27 by
circulating varlilumab, as has been reported for the anti-VEGF
antibody (bevacizumab) stabilizing serum VEGF levels.20 However,
this could also reflect an increase in the level of CD27 shedding
from activated T cells, and increased soluble CD27 is consistent
with an inflammatory effect that has been associated with improved
response to immunotherapy.15
Other pharmacodynamic effects include transient upregulation of
inflammatory chemokines and cytokines across all dose levels
within hours of varlilumab administration. These effects are
consistent with immune activation and with our observations of
varlilumab in solid tumor patients.15 Notably, no cases of hyperprogression were seen. In contrast to the significant decrease of
Tregs in patients with solid tumors, we observed a variable effect of
varlilumab on Tregs in hematologic malignancies, with only a subset
having pronounced decreases in circulating Tregs.
Combination strategies targeting multiple nonredundant pathways
regulating tumor burden and immune responses may be synergistic
and enhance antitumor immune responses as shown in preclinical
studies. In particular, recent studies show that CD27 and PD-1
pathways synergize in their antitumor effects by directing complementary transcriptional programs, leading to enhanced survival and
cytotoxicity of T cells.21 Mice inoculated with the aggressive BCL1
lymphoma and treated with varlilumab and PD-1 blockade showed
statistically significant prolonged survival than mice that were not
treated or given each of the 2 compounds separately. In addition,
12 MAY 2020 x VOLUME 4, NUMBER 9

studies by Lim et al22 reported synergy when combining CD27
agonist monoclonal antibodies with anti-CD20 antibody therapy in
lymphoma models. These studies pointed to a new mechanism of
CD27 anti-tumor activity through the release of cytokines that
attract and activate innate cells (natural killer and macrophage)
which promote the antitumor effect of CD20 antibody. Synergistic
activity23 has also been reported in animal models with varlilumab
and the agonist anti-CD40 monoclonal antibody CDX-1140,24
which has recently entered clinical trials.
Collectively, these data support the safety and activity of varlilumab
in hematologic malignancies. However, based on the modest
single-agent activity of varlilumab, future studies will explore
combination therapy to enhance overall outcomes for patients.
Ongoing studies include varlilumab in combination with nivolumab
in refractory non-Hodgkin lymphoma and varlilumab in combination with rituximab in CD201 rituximab-refractory non-Hodgkin
lymphoma.
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